|
Synonyms: AOC 1020 | AOC-1020 | del-brax
Compound class:
Nucleic acid
Comment: Delpacibart braxlosiran is structurally a monoclonal antibody (mAb)-oligonucleotide conjugate (AOC) in which the mAb binds the transferrin receptor (TFRC;) for targeted delivery of a small interfering RNA (siRNA) payload that targets double homeobox 4 (DUX4) mRNA [1].
This entry provides information on the siRNA as the component that mediates the agent's intended pharmacodynamic effect. Further details about the parental anti-TFRC mAb are provided in the delpacibart entry. To improve pharmacokinetics and RNA binding the nucleotides in braxlosiran (siDUX4.6) are chemically modified (2'-O-methyl/2'-MOE and 2'-deoxy-2'-fluoro/2'-F monomers), with a mixed phosphorothioate/phosphate backbone. The delpacibart component is attached at the 5' end of the passenger strand via a malemide linker Aberrant activation of the DUX4 gene in skeletal muscle causes the progressive muscle-wasting disease facioscapulohumeral muscular dystrophy (FSHD). The braxlosiran siRNA is intended to reduce DUX4 expression in skeletal muscle [1]. |
| No information available. |
Summary of Clinical Use ![]() |
| Delpacibart braxlosiran (AOC-1020) was progressed as a clinical candidate for its potential to treat facioscapulohumeral muscular dystrophy. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT06547216 | Phase 2 Open-label Extension Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) | Phase 2 Interventional | Avidity Biosciences, Inc. | ||
| NCT07038200 | A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD | Phase 3 Interventional | Avidity Biosciences, Inc. | ||